The Case for Less Expensive Biotech Drugs episode artwork

EPISODE · Aug 19, 2009 · 14 MIN

The Case for Less Expensive Biotech Drugs

from Clinician's Roundtable

Host: Bruce Japsen Guest: Sumant Ramachandra, MD While drug makers and consumer groups lobby Congress and the Obama administration on the best way to bring cheaper versions of biotech drugs to market, a U.S. company is already doing so overseas. How does this work and what are the prospects for biogenerics in the U.S. Dr. Sumant Ramachandra, Chief Scientific Officer at Hospira Inc. tells host Bruce Japsen about the company's work bringing cheaper biotech drugs to market.

Episode metadata supplied by the publisher feed · Published Aug 19, 2009

Embed this episode

NOW PLAYING

The Case for Less Expensive Biotech Drugs

0:00 14:59

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Clinician's Roundtable?

This episode is 14 minutes long.

When was this Clinician's Roundtable episode published?

This episode was published on August 19, 2009.

Can I download this Clinician's Roundtable episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!